Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01300-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Mason J Handford und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Physiology and Biochemistry Department, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Antimalarials, Aminoquinolines, Plasmodium falciparum, Malaria, Falciparum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. Department of Defense, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Plasmodium falciparum, the deadliest causative agent of malaria, continues to evade eradication efforts through widespread drug resistance. The recent development of ADC-028 , a 4-aminoquinoline antimalarial with excellent activity and pharmacokinetic properties, prompted the investigation of bisquinoline analogs featuring similar structural motifs. Here, we describe a structure-activity relationship study that guided the optimization of compounds with key features, including the 4-anilinoquinoline core and diverse bridging linkers. Several analogs exhibited potent in vitro activity (IC 50 < 20 nM) against both drug-sensitive and multidrug-resistant P. falciparum strains, while maintaining favorable cytotoxicity profiles. Among them, 25 demonstrated improved intrinsic metabolic stability (t 1/2 = 121 min) and potent in vivo efficacy (ED 50 = 0.32 mg/kg/day), achieving complete curative protection at a reduced dose compared to ADC-028. While 25 showed moderately reduced oral bioavailability (F = 43%) and a shorter half-life (T 1/2 = 27.2 h) relative to ADC-028, its enhanced in vivo efficacy underscores its therapeutic potential. This work highlights a promising path forward in developing antimalarials that retain the efficacy of legacy compounds while overcoming modern resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical Physiology and Biochemistry Department, Oregon Health & Science University, Portland, Oregon, USA.
- Experimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
- Department of Chemistry, Portland State University, Portland, Oregon, USA.
- Molecular Microbiology and Immunology Department, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Mason J Handford, Michael K Riscoe
Förderung
- NIH HHS
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- National Institutes of Health
Zitieren
APA
Handford, M. J., Li, Y., Riscoe, T., Zhang, X., Kelly, J. X., & Riscoe, M. K. (2026). Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01300-25
Vancouver
Handford MJ, Li Y, Riscoe T, Zhang X, Kelly JX, Riscoe MK. Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01300-25
BibTeX
@article{Handford2026,
author = {Handford, Mason J and Li, Yuexin and Riscoe, Terry and Zhang, Xiaowei and Kelly, Jane X and Riscoe, Michael K},
title = {Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01300-25}
}
EUVIMED